AbbVie Acquires Gilgamesh’s Psychedelic MDD Program For Up To $1.2B

What You Should Know: – AbbVie and Gilgamesh Pharmaceuticals Inc. have announced a definitive agreement for AbbVie to acquire Gilgamesh’s lead investigational candidate, bretisilocin, which is in clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD). – The deal is valued at up to $1.2B, which includes an upfront payment and ... Read More